Jefferies analyst Eun Yang downgraded Radius Health (RDUS) to Hold saying meaningful share upside from current levels is unlikely after the stock rallied 25% on the "not so strong" Phase 3 data for Amgen's (AMGN) potential competitor romosozumab. Even though romosozumab's data are not as strong as Radius Health's abaloparatide-SC, osteoporosis experts don't view the latter the drug as more competitive, Yang tells investors in a research note. Neither anabolic drug has been shown to reduce hip fractures, which is the most unmet need, the analyst points out. Yang keeps a $37 price target for shares of Radius. The biopharmaceutical company closed yesterday down $1.04 to $32.83.